A study to compare laser treatment alone versus laser treatment plus the test serum for facial dark spots and acne marks.

Evaluation of the efficacy and tolerability of MelaB3 serum in adjunct to Non-ablative Q-switch Nd:YAG laser procedure compared to laser procedure alone in the management of Melasma and PIHP post-acne in adults from India - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104862

Enrollment

Registered

2026-02-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Laser procedure + MelaB3 serum (Pre- and Post-Laser Use): Trial participants will apply the test serum at home twice daily (morning and evening) before and after the laser procedure and

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female participants aged above 18 to 65 years 2. Fitzpatrick skin phototypes III to VI 3. Trial participants must present with only one facial pigmentary condition either melasma or PIHP 4. Trial participants in good general and mental health in the opinion of the investigator 5. Trial participants demonstrating understanding of the study procedures restrictions and willingness to participate as evidenced by voluntary written informed consent and having received a signed and dated copy of the consent form

Exclusion criteria

Exclusion criteria: 1.Female trial participants who are pregnant or breastfeeding, or who plan to become pregnant during the study (If the last menstrual period (LMP) is more than 6 weeks prior to the Screening visit, a UPT will be performed). 2.Female trial participant who gave birth less than 3 months prior to Day -14, who is pregnant, breast-feeding or who plans to become pregnant during the study. 3.Male trial participant with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline. 4.Trial participant with known allergy to any ingredients of the test products (tested product and sunscreen). 5. Trial participant with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc

Design outcomes

Primary

Measure	Time frame
Evaluate & Compare the efficacy levels between treatment groups by Change from Baseline in participants with melasma & PIH by dermatological and instrumental assessmentsTimepoint: D1,D28, D56, D84	—

Secondary

Measure	Time frame
Evaluate & Compare the efficacy & safety of the serum by participant self-assessment questionnaire and by dermatological evaluation.Timepoint: D1,D28, D56, D84	—

Countries

India

Contacts

Public ContactSudhanthiran S

MS Clinical Research Pvt. Ltd

ritambhara@msclinical.com08040917253

Outcome results